File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Systemic treatment for triple negative breast cancer in older patients: A Young International Society of Geriatric Oncology Review Paper

TitleSystemic treatment for triple negative breast cancer in older patients: A Young International Society of Geriatric Oncology Review Paper
Authors
KeywordsAssessment
Chemotherapy
Geriatric assessment
Immunotherapy
Older patients
Triple negative breast cancer
Issue Date23-Jan-2022
PublisherElsevier
Citation
Journal of Geriatric Oncology, 2022, v. 13, n. 5, p. 563-571 How to Cite?
AbstractBreast cancer is the most common type of cancer affecting women worldwide and its risk increases with age. Compared with other breast cancer subtypes, triple negative breast cancer (TNBC) behaves more aggressively, with earlier relapses and poorer survival outcomes. Although the incidence of TNBC decreases with age, it still affects about 10% of older women with breast cancer. The management of TNBC in older patients is particularly challenging as chemotherapy is the main treatment choice in both early and advanced diseases and older patients are often prone to increased treatment-related toxicities. This review highlights the specific considerations in this vulnerable group of patients and summarizes the current evidence for TNBC management in older adults from early to late stage of disease.
Persistent Identifierhttp://hdl.handle.net/10722/345492
ISSN
2023 Impact Factor: 3.0
2023 SCImago Journal Rankings: 1.052

 

DC FieldValueLanguage
dc.contributor.authorChan, Wing Lok-
dc.contributor.authorMarinho, Joana-
dc.contributor.authorChavarri-Guerra, Yanin-
dc.contributor.authorHincapie-Echeverri, Jacobo-
dc.contributor.authorVelasco, Rogelio N-
dc.contributor.authorAkagunduz, Baran-
dc.contributor.authorRoy, Mukul-
dc.contributor.authorKwong, Wing Tung Gobby-
dc.contributor.authorWu, Wing Fong-
dc.contributor.authorBattisti, Nicolò Matteo Luca-
dc.contributor.authorSoto-Perez-de-Celis, Enrique-
dc.date.accessioned2024-08-27T09:09:06Z-
dc.date.available2024-08-27T09:09:06Z-
dc.date.issued2022-01-23-
dc.identifier.citationJournal of Geriatric Oncology, 2022, v. 13, n. 5, p. 563-571-
dc.identifier.issn1879-4068-
dc.identifier.urihttp://hdl.handle.net/10722/345492-
dc.description.abstractBreast cancer is the most common type of cancer affecting women worldwide and its risk increases with age. Compared with other breast cancer subtypes, triple negative breast cancer (TNBC) behaves more aggressively, with earlier relapses and poorer survival outcomes. Although the incidence of TNBC decreases with age, it still affects about 10% of older women with breast cancer. The management of TNBC in older patients is particularly challenging as chemotherapy is the main treatment choice in both early and advanced diseases and older patients are often prone to increased treatment-related toxicities. This review highlights the specific considerations in this vulnerable group of patients and summarizes the current evidence for TNBC management in older adults from early to late stage of disease.-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofJournal of Geriatric Oncology-
dc.subjectAssessment-
dc.subjectChemotherapy-
dc.subjectGeriatric assessment-
dc.subjectImmunotherapy-
dc.subjectOlder patients-
dc.subjectTriple negative breast cancer-
dc.titleSystemic treatment for triple negative breast cancer in older patients: A Young International Society of Geriatric Oncology Review Paper-
dc.typeArticle-
dc.identifier.doi10.1016/j.jgo.2022.01.002-
dc.identifier.pmid35078741-
dc.identifier.scopuseid_2-s2.0-85123352365-
dc.identifier.volume13-
dc.identifier.issue5-
dc.identifier.spage563-
dc.identifier.epage571-
dc.identifier.issnl1879-4068-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats